Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Kyung Jin Eoh; 박형석; JI SOO PARK; 이승태; 한정우; 이정윤; Sangwun Kim; 김성훈; 김영태; 남은지

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Recommendations

Search

Type: Academic journal

Author: Kyung Jin Eoh 박형석 JI SOO PARK 이승태 한정우 이정윤 Sangwun Kim 김성훈 김영태 남은지

Journal: 대한암학회 Cancer Research and Treatment Cancer Research and Treatment 제49권 제2호 KCI Accredited Journals

Published: 2017.1

Pages: 408 - 415 (8page)

Usage

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Abstract· Keywords

Report Errors

Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9%) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patients with BRCA1/2mutation had longer OS than those with BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.

#Ovarian epithelial cancer #BRCA1 #BRCA2 #Prognosis

No content found

References (24)

Add References

Aida H / 1998 / Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 / Clin Cancer Res 4 : 235 ~ 240

Calo V / 2010 / The clinical significance of unknown sequence variants in BRCA genes / Cancers(Basel) 2 : 1644 ~ 1660

Chen S / 2006 / Characterization of BRCA1 and BRCA2 mutations in a large United States sample / J Clin Oncol 24 : 863 ~ 871

Choi MC / 2015 / Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients : finding founder mutations / Int J Gynecol Cancer 25 : 1386 ~ 1391

Easton DF / 2007 / A systematic genetic assessment of 1, 433sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes / Am

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!